Invizius

Invizius is a biotech company who are developing treatments to suppress immune responses to dialysis. Invizius spun-out of the University of Edinburgh in 2018 following research by the current CTO and co-founder Dr Andy Herbert.

Over 3 million people in the UK live with chronic kidney disease and many require dialysis to survive, putting themselves at risk for further health complications and having a negative impact on their quality of life. Cardiovascular disease continues to be the primary cause of mortality among individuals undergoing dialysis. Presently, nearly half of all dialysis patients succumb to cardiovascular complications, resulting in a life expectancy on dialysis that is only one-third of that observed in the general population.

MBM Commercial have provided legal advice to Invizius from spin out to fundraise. In 2021 the firm completed a £5.3m Series A fundraise. Getting to this point requires lots of hard work and determination - and, of course, good lawyers.

MBM Commercial takes pride in providing support to start-ups and spin-outs like Invizius through a dedicated team. We actively seek to engage with and support early-stage companies, joining them on their journey and providing key legal advice as they grow.

Invizius have instructed MBM on several matters beyond fundraising work, taking advantage of the different services that MBM offers including our HolisticHR, Company Secretarial Service and Registered Office Services. MBM Commercial have also provided support and guidance on GDPR and critical contracts. This allows the pioneers at Invizius to spend more time concentrating on improving the quality of life for dialysis patients with the reassurance that MBM are there to support them when it is required.